Neurocrine says Indiplon may need more testing

Share this article:
The company developing Indiplon says federal regulators may require additional clinical tests before approving the experimental insomnia drug. Last month Neurocrine Biosciences and Pfizer received an approvable letter on the 5 mg. and 10-mg. doses of indiplon but a rejection letter on the 15-mg. strength. After reviewing the letters, Neurocrine said the FDA “may require” additional clinical trials on the lower doses and “will likely” require additional clinical data on the higher dose.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.